Gan & Lee's Monthly Bofanglutide Holds Weight in Phase III Trial
Image
Beijing – November 04, 2026 -- Gan & Lee Pharmaceuticals (Stock Code: 603087.SH) reported that once-monthly bofanglutide met the primary endpoint of its Phase IIIb GRADUAL-3 study, holding body weight near baseline over 24 weeks while the placebo group changed by 8.52%.
Both monthly dose groups beat placebo at P0.0001
Mean body-weight changes from baseline were 0.41% in the 24 mg once-monthly group and -0.12% in the 48 mg group, against 8.52% for placebo. Both comparisons reached P0.0001. The primary endpoint was the percentage change in body weight from baseline after 24 weeks.